High-dose methylprednisolone in the treatment of multiple sclerosis

Multiple Sclerosis Therapeutics

Volumn , Issue , 2007, Pages 515-533

  Fox, Robert J ^a   Kinkel, R Philip ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149465309     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (142)

1. Schimmer BP, Parker KL. Adrenocorticotropic hormone, adrenocortical steroids and their synthetic analogs, inhibitors of the synthesis and actions of hormones. In Hardman JG, Limbird LE, eds. Goodman and Gilman's Pharmacological Basic of Therapeutics. New York: McGraw-Hill, 1996: 1459-85
2. Vree TB, Lagerwerf AJ, Verwey-van Wissen CP, Jongen PJ. High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. J Chro-matogr B Biomed Sci Appl 1999; 732: 337-48
3. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J Clin Invest 1979; 64: 145-54
4. Defer GL, Barre J, Ledudal P, et al. Methyl-prednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995; 35: 143-8
5. Hayball PJ, Cosh DG, Ahern MJ, et al. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992; 42: 85-8
6. Narang PK, Wilder R, Chatterji DC, et al. Systemic bioavailability and pharmacokinetics of methylpred-nisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. Biopharm Drug Dispos 1983; 4: 233-48
7. Chassard D, Banzet O, Lamy F, et al. Tolérance gastro-duodénale de la méthylprednisolone. Etude de la voie orale versus voie veineuse chez le volontaire sain. Presse Med 1994; 23: 515-17
8. Metz LM, Sabuda D, Hilsden RJ, et al. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology 1999; 53: 2093-6
9. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-41
10. Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol 1993; 7: 4-11
11. Boumpas DT, Chrousos GP, Wilder RL, et al. Gluco-corticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119:1198-208
12. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 1990; 249: 1266-72
13. Ing NH, O'Malley BW. The steroid hormone receptor superfamily: molecular mechanisms of action. In Weintraub BD, ed. Molecular Endocrinology: Basic Concepts and Clinical Correlations. New York: Raven Press, 1995: 195-215
14. Rousseau GG. Control of gene expression by gluco-corticoid hormones. Biochem J 1984; 224: 1-12
15. Borski RJ. Nongenomic membrane actions of gluco-corticoids in vertebrates. Trends Endocrinol Metab 2000; 11: 427-36
16. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990; 62: 1189-204
17. Planey SL, Litwack G. Glucocorticoid-induced apop-tosis in lymphocytes. Biochem Biophys Res Commun 2000; 279: 307-12
18. Xu J, Fan G, Chen S, et al. Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res Mol Brain Res 1998; 59: 135-42
19. Oudega M, Vargas CG, Weber AB, et al. Long-term effects of methylprednisolone following transection of adult rat spinal cord. J Histochem Cytochem 1999; 11: 2453-64
20. Abraham IM, Harkany T, Horvath KM, Luiten PGM. Action of glucocorticoids on survivial of nerve cells: promoting neurodegeneration or neuroprotection? J Neurogenet 2001; 13: 749-60
21. Hall ED. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol 1993; 13: 415-32
22. Crockard AD, Treacy MT, Droogan AG, et al. Transient immunomodulation by intravenous methyl-prednisolone treatment of multiple sclerosis. Mult Scler 1995; 1: 20-4
23. Fauci AS, Dale DC, Balow JE. Glucocorticoid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 304-15
24. Trotter JL, Garvey WF. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 1980; 30: 702-8
25. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996; 60: 563-72
26. Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-alpha secretion. Inflamm Res 1997; 46: 447-51
27. Gayo A, Mozo L, Suâarez A, et al. Glucocorti-coids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998; 85: 122-30
28. Wandinger KP, Wessel K, Trillenberg P, et al. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neurol Scand 1998; 97: 359-65
29. Crockard AD, Treacy MT, Droogan AG, Hawkins SA. Methylprednisolone attenuates interferon-beta induced expression of HLA-DR on monocytes. J Neuroimmunol 1996; 70: 29-35
30. Lujan S, Masjuan J, Roldan E, et al. The expression of integrins on activated T-cells in multiple sclerosis. Effect of intravenous methylprednisolone treatment. Mult Scler 1998; 4: 239-42
31. Ossege LM, Sindern E, Voss B, Malin JP. Cortico-steroids induce expression of transforming-growth-factor-beta1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis. J Neuro-immunol 1998; 84: 1-6
32. Gelati M, Lamperti E, Dufour A, et al. IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings. Ital J Neurol Sci 1997; 18: 191-4
33. Petelin Z, Brinar V, Petravic D, et al. CD95/Fas expression on peripheral blood T lymphocytes in patients with multiple sclerosis: effect of high-dose methylprednisolone therapy. Clin Neurol Neurosurg 2004; 106: 259-62
34. Martinez-Caceres EM, Barrau MA, Brieva L, et al. Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 2002; 127: 165-71
35. Leussink VI, Jung S, Merschdorf U, et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58: 91-7
36. Loughlin AJ, Woodroofe MN, Cuzner ML. Modulation of interferon-gamma-induced major histocom-patibility complex class II and Fc receptor expression on isolated microglia by transforming growth factorbeta 1, interleukin-4, noradrenaline and glucocorti-coids. Immunology 1993; 79: 125-30
37. Kirk PF, Williams JD, Petersen MM, Compston DA. The effect of methylprednisolone on monocyte eico-sanoid production in patients with multiple sclerosis. J Neurol 1994; 241: 427-31
38. Ruiz P, Gomez F, King M, et al. In vivo glucocorti-coid modulation of guinea pig splenic macrophage Fc gamma receptors. J Clin Invest 1991; 88: 149-57
39. Cupps TR, Gerrard TL, Falkoff RJ, et al. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest 1985; 75: 754-61
40. Gold R, Pepinsky RB, Zettl UK, et al. Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat. J Neuroimmunol 1996; 69: 157-64
41. Crofford LJ, Wilder RL, Ristimèaki AP, et al. Cyclo-oxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101
42. Gelati M, Corsini E, Dufour A, et al. Reduced adhesion of PBMNCs to endothelium in methylpred-nisolone-treated MS patients: preliminary results. Acta Neurol Scand 1997; 96: 283-92
43. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of cortico-steroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Nat Acad Sci USA 1992; 89: 9991-5
44. Elovaara I, Lalla M, Spare E, et al. Methyl-prednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 1998; 51: 1703-8
45. Gelati M, Corsini E, Dufour A, et al. High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium. Can J Neurol Sci 2000; 27: 241-4
46. Kraus J, Oschmann P, Engelhardt B, et al. Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methyl-prednisolone treatment and relevance as markers for disease activity. Acta Neurol Scand 2000; 101: 135-9
47. Rosenberg GA, Dencoff JE, Correa N Jr, et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996; 46: 1626-32
48. Mirowska D, Wicha W, Czlonkowski A, et al. Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 2004; 146: 171-5
49. Gelati M, Corsini E, De Rossi M, et al. Methylpred-nisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 2002; 59: 774-80
50. Compston DAS, Milligan NM, Hughes PJ, et al. A double-blind controlled trial of high dose methyl-prednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry 1987; 50: 517-22
51. Durelli L, Poccardi G, Cavallo R. CD8+ high CD11b+ low T cells (T suppressor-effectors) in multiple sclerosis cerebrospinal fluid are increased during high dose corticosteroid treatment. J Neuroimmunol 1991; 31: 221-8
52. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-13
53. Anderson TJ, Donaldson IM, Sheat JM, George PM. Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters. Aust NZ J Med 1990; 20: 794-7
54. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylpred-nisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 2000; 7: 281-9
55. Wang HY, Matsui M, Araya S, et al. Immune parameters associated with early treatment effects of highdose intravenous methylprednisolone in multiple sclerosis. J Neurol Sci 2003; 216: 61-6
56. Warren KG, Catz I, Jeffrey VM, Carroll DJ. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and antimyelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci 1986; 13: 25-30
57. Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DPTA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylpred-nisolone. Neurology 1992; 42: 63-7
58. Franciotta D, Piccolo G, Zardini E, et al. Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. Acta Neurol Scand 1997; 95: 275-9
59. Trojano M, Avolio C, Simone IL, et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 1996; 47: 1535-11
60. Spuler S, Yousry T, Scheller A, et al. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 1996; 66: 57-64
61. Yamashita T, Ando Y, Obayashi K, et al. Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997; 153: 32-4
62. Sait Keles M, Taysi S, Aksoy H, et al. The effect of corticosteroids on serum and cerebrospinal fluid nitric oxide levels in multiple sclerosis. Clin Chem Lab Med 2001; 39: 827-9
63. Keles MS, Taysi S, Sen N, et al. Effect of cortico-steroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci 2001; 28: 141-3
64. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-8
65. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-81
66. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-74
67. Nakazawa F, Matsuno H, Yudoh K, et al. Corticos-teroid treatment induces chondrocyte apoptosis in an experimental arthritis model and in chondrocyte cultures. Clin Exp Rheumatol 2002; 20: 773-81
68. Watters JJ, Campbell JS, Cunningham MJ, et al. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997; 138: 4030-3
69. Meyer R, Weissert R, Diem R, et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 2001; 21: 6214-20
70. Diem R, Hobom M, Maier K, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuro-protective pathway. J Neurosci 2003;23: 6993-7000
71. Glaser GH, Merritt HH. Effects of ACTH and cortisone in multiple sclerosis. Trans Am Neurol Assoc 1951; 56: 130-3
72. Myers LW. Treatment of multiple sclerosis with ACTH and corticosteroids. In Rudick RA, Goodkin DE, eds. Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives. London: SpringerVerlag, 1992: 135-56
73. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo - final report. Neurology 1970; 20: 1-59
74. Bell PR, Briggs JD, Calman KC, et al. Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone. Lancet 1971; 1: 876-80
75. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone 'pulse' therapy in diffuse proliferative lupus nephritis. Lancet 1976; 1: 163-6
76. de Torrente A, Popovtzer MM, Guggenheim SJ, Schrier RW. Serious pulmonary hemorrhage, glomeru-lonephritis, and massive steroid therapy. Ann Intern Med 1975; 83: 218-19
77. Bolton WK, Couser WG. Intravenous pulse methyl-prednisolone therapy of acute crescentic rapidly progressive glomerulonephritis. Am J Med 1979; 66: 495-502
78. Neild GH, Lee HA. Methylprednisolone pulse therapy in the treatment of polyarteritis nodosa. Postgrad Med J 1977; 53: 382-7
79. Fan PT, Yu DT, Targoff C, Bluestone R. Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by 'pulse' methylprednisolone. Transplantation 1978; 26: 266-7
80. Dowling PC, Bosch VV, Cook SD. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 1980; 30: 33-6
81. Buckley C, Kennard C, Swash M. Treatment of acute exacerbations of multiple sclerosis with intravenous methyl-prednisolone. J Neurol Neurosurg Psychiatry 1982; 45: 179-80
82. Newman PK, Saunders M, Tilley PJ. Methylpre-dnisolone therapy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1982; 45: 941-2
83. Goas JY, Marion JL, Missoum A. High dose intravenous methyl prednisolone in acute exacerbations of multiple sclerosis. J Neurol Neurosurg Psychiatry 1983; 46: 99
84. Abbruzzese G, Gandolfo C, Loeb C. 'Bolus' methyl-prednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci 1983; 4: 169-72
85. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985; 48:157-9
86. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969-71
87. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylpred-nisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-16
88. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-34
89. Miller DM, Weinstock-Guttman B, Bethoux F, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000; 6: 267-73
90. Filippini G, Brusaferri F, Sibley W, et al. Corti-costeroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (4): CD001331
91. Bindoff L, Lyons PR, Newman PK, Saunders M. Methylprednisolone in multiple sclerosis: a comparative dose study. J Neurol Neurosurg Psychiatry 1988; 51: 1108-9
92. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-20
93. La Mantia L, Eoli M, Milanese C, et al. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994; 34: 199-203
94. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6
95. Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different doses of methylpred-nisolone in MS. A clinical and MRI study. Neurology 1998; 50: 1833-6
96. Barkhof F, Polman C. Oral or intravenous methyl-prednisolone for acute relapses of MS? Lancet 1997; 349: 893-4
97. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-8
98. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol 1993; 111: 773-5
99. Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 1995; 113: 136-7
100. Cleary PA, Beck RW, Bourque LB, et al. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol 1997; 17: 18-23
101. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47
102. Cazzato G, Mesiano T, Antonello R, et al. Doubleblind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 1995; 35: 193-8
103. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51: 239-45
104. Sears ES, Tindall RS, Zarnow H. Active multiple sclerosis. Enhanced computerized tomographic imaging of lesions and the effect of corticosteroids. Arch Neurol 1978; 35: 426-34
105. Troiano R, Hafstein M, Ruderman M, et al. Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol 1984; 15: 257-63
106. Troiano RA, Hafstein MP, Zito G, et al. The effect of oral corticosteroid dosage on CT enhancing multiple sclerosis plaques. J Neurol Sci 1985; 70: 67-72
107. Stefoski D, Davis FA, Schauf CL. Acute improvement in exacerbating multiple sclerosis produced by intravenous administration of mannitol. Ann Neurol 1985; 18: 443-50
108. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DPTA enhancement after high-dose intravenous methylpred-nisolone in multiple sclerosis. Neurology 1991; 41: 1219-22
109. Miller DH, Thompson AJ, Morrisey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-3
110. Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991; 41: 1349-54
111. Barkhof F, Tas MW, Frequin ST, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994; 36: 382-7
112. Sellebjerg F, Jensen CV, Larsson HB, Frederiksen JL. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler 2003; 9: 102-7
113. Kesselring J, Miller DH, MacManus DG, et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methyl-prednisolone. J Neurol Neurosurg Psychiatry 1989; 52: 14-17
114. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33: 480-9
115. Fox RJ, Fisher E, Tkach J, et al. Brain atrophy and magnetization transfer ratio following methylpred-nisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler 2005; 11: 140-5
116. Rao AB, Richert N, Howard T, et al. Methyl-prednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002; 59: 688-94
117. Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 2002; 8: 415-19
118. Gasperini C, Pozzilli C, Bastianello S, et al. Effects of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998; 50: 403-6
119. Hickman SJ, Kapoor R, Jones SJ, et al. Cortico-steroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry 2003; 74: 1139-41
120. Schocke MF, Berger T, Felber SR, et al. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. Neuroimaging Clin N Am 2003; 20: 1253-63
121. Cohen J, Calabresi P, Fisher E, et al. Rationale, design, and baseline data for the Avonex Combination Trial. Mult Scler 2005; 11 (Suppl 1): S155
122. Lyons PR, Newman PK, Saunders M. Methyl-prednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 1988; 51: 285-7
123. Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment? Ann Rheum Dis 1990; 49: 265-7
124. Levic Z, Micic D, Nikolic J, et al. Short-term high dose steroid therapy does not affect the hypothala-mic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest 1996; 19: 30-4
125. Miro J, Amado JA, Pesquera C, et al. Assessment of the hypothalamic-pituitary-adrenal axis function after corticosteroid therapy for MS relapses. Acta Neurol Scand 1990; 81: 524-8
126. Pryse-Phillips WEM, Chandra RK, Rose B. Anaphy-lactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis. Neurology 1984; 34: 1119-21
127. van den Berg JS, van Eikema Hommes OR, Wuis EW, et al. Anaphylactoid reaction to intravenous methyl-prednisolone in a patient with multiple sclerosis. J Neurol Neurosurg psychiatry 1997; 63: 813-14
128. Burgdorff T, Venemalm L, Vogt T, et al. IgE-medi-ated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol 2002; 89: 425-8
129. Kuga A, Futamura N, Funakawa I, Jinnai K. Allergic skin rashes by methylprednisolone in a case with multiple sclerosis. Rinsho Shinkeigaku 2004; 44: 691-4
130. Brunner R, Schaefer D, Hess K, et al. Effect of corti-costeroids on short-term and long-term memory. Neurology 2005; 64: 335-7
131. Uttner I, Mèuller S, Zinser C, et al. Reversible impaired memory induced by pulsed methylpred-nisolone in patients with MS. Neurology 2005; 64: 1971-3
132. Cosman F, Nieves J, Komar L, et al. Fracture history and bone loss in patients with MS. Neurology 1998; 51: 1161-5
133. Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glu-cocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004; 89: 4923-8
134. Ardissone P, Rota E, Durelli L, et al. Effects of high doses of corticosteroids on bone metabolism. J Endo-crinol Invest 2002; 25: 129-33
135. Schwid SR, Goodman AD, Puzas JE, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996; 53: 753-7
136. Frediani B, Falsetti P, Bisogno S, et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 2004; 31: 1083-7
137. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791-801
138. Wakefield D, Jennings A, McCluskey PJ. Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Exp Ophthalmol 2000; 28: 103-6
139. Kinkel RP, Simon JH, Baron B. Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: potential outcome measures for future multiple sclerosis 'prevention' trials. Mult Scler 1999; 5: 307-12
140. Jacobs LD, Beck RW, Simon JH, et al. The effect of initiating interferon beta-1a therapy during a first demyelinating event on the development of clinically definite multiple sclerosis. N Engl J Med 2000; 343: 898-904
141. Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50-6
142. Schmidt J, Metselaar JM, Gold R. Intravenous lipo-somal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. J Histochem Cytochem 2003; 51: 1241-4